联环药业(600513.SH)：控股子公司获得《药品补充申请批准通知书》

Core Viewpoint - The company, Lianhuan Pharmaceutical (600513.SH), announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Atropine Sulfate Injection [1] Group 1 - Atropine Sulfate Injection is primarily used for various visceral spasms, such as gastrointestinal colic and bladder irritability [1] - The drug is also indicated for pre-anesthesia medication, severe sweating and salivation, and bradyarrhythmias caused by excessive vagal nerve stimulation [1] - Additionally, it can be used for shock treatment and to counteract poisoning from organophosphate esters [1]